Arteriosclerosis, thrombosis, and vascular biology · 2009
Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and nuclear factor-kappaB.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aoki Tomohiro, Kataoka Hiroharu, Ishibashi Ryota, Nozaki Kazuhiko, Morishita Ryuuichi, Hashimoto Nobuo
Аннотация
BACKGROUND: Reduced extracellular matrix is a prominent feature of cerebral aneurysms (CAs). We previously reported excessive ECM degradation in CA walls. In the present study, we examined collagen biosynthesis in CA walls and the molecular mechanisms underlying it in CA progression.
METHODS AND RESULTS: RT-PCR and immunohistochemistry showed reduced expression of procollagen type I, III, and lysyl oxidase (LOX) in CA walls. Treatment with the LOX inhibitor beta-aminopropionitrile resulted in enhanced progression of CA. Expression of procollagen type I, III, and LOX was inhibited by interleukin-1beta (IL-1beta) in cultured rat aortic smooth muscle cells (RASMCs) in vitro. Nuclear factor kappa-B (NF-kappaB) was activated in IL-1beta-stimulated RASMCs, and treatment with NF-kappaB decoy oligodeoxynucleotides (ODN) restored reduced expression of procollagen type I, III, and LOX in vitro. NF-kappaB decoy ODNs ameliorated the expression of procollagen type I, III, and LOX in CA walls in vivo.
CONCLUSIONS: Collagen biosynthesis was significantly inhibited at the transcriptional level and in the posttranscriptional enzymatic modification in CA walls through upregulated expression of IL-1beta and the NF-kappaB pathway. Reduced collagen biosynthesis may contribute to CA progression, and inhibition of this process may lead to the prevention of the progression and rupture of CAs.
METHODS AND RESULTS: RT-PCR and immunohistochemistry showed reduced expression of procollagen type I, III, and lysyl oxidase (LOX) in CA walls. Treatment with the LOX inhibitor beta-aminopropionitrile resulted in enhanced progression of CA. Expression of procollagen type I, III, and LOX was inhibited by interleukin-1beta (IL-1beta) in cultured rat aortic smooth muscle cells (RASMCs) in vitro. Nuclear factor kappa-B (NF-kappaB) was activated in IL-1beta-stimulated RASMCs, and treatment with NF-kappaB decoy oligodeoxynucleotides (ODN) restored reduced expression of procollagen type I, III, and LOX in vitro. NF-kappaB decoy ODNs ameliorated the expression of procollagen type I, III, and LOX in CA walls in vivo.
CONCLUSIONS: Collagen biosynthesis was significantly inhibited at the transcriptional level and in the posttranscriptional enzymatic modification in CA walls through upregulated expression of IL-1beta and the NF-kappaB pathway. Reduced collagen biosynthesis may contribute to CA progression, and inhibition of this process may lead to the prevention of the progression and rupture of CAs.